文献速递儿童神经与发育行为儿童内分泌与遗传代谢

早期儿童癫痫与基因检测的新兴作用

Early-Life Epilepsies and the Emerging Role of Genetic Testing.
PubMed 文献 · JAMA Pediatr · 2017-01-01

这项前瞻性队列研究纳入美国17家儿童医院775例3岁前新诊断癫痫患儿,发现48.1%接受基因检测者中40.4%检出致病性变异,且无论关键临床特征如何,诊断率均较高,提示应把全面基因检测纳入早期评估。

要点

  • 早期儿童癫痫基因检测诊断率为40.4%,测序方法阳性率高于染色体微阵列。
  • 无论癫痫延迟、痉挛和年龄如何,诊断率均大于15%。
  • 应把以测序为主的全面基因检测纳入新发早期癫痫的初始评估。

核心结论

  • 基因检测尤其是广泛测序方法在新诊断的早期儿童癫痫中诊断率高,且不受关键临床特征影响。

研究设计与样本

  • 前瞻性队列研究,2012年3月1日至2015年4月30日从17家美国儿童医院招募775例3岁前新诊断癫痫患儿并随访1年。

主要发现

  • 775例患儿中95例(12.3%)有获得性脑损伤,剩余680例中327例(48.1%)接受基因检测,132例(40.4%;95%CI 37%-44%)检出致病性变异。
  • 核型分析59例中26例(44.1%)、微阵列188例中32例(17.0%)、癫痫 panel 114例中31例(27.2%)、全外显子33例中11例(33.3%)、线粒体 panel 20例中4例(20.0%)、其他检测94例中28例(29.8%)检出变异。
  • 446例病因不明患儿中180例(40.4%)接受检测,48例(26.7%;95%CI 18%-34%)检出致病性变异。
  • 无论癫痫延迟、痉挛和年龄如何,诊断率均大于15%;癫痫 panel(96例中28例,29.2%;P<.001)和全外显子(18例中5例,27.8%;P=.02)诊断率高于染色体微阵列(101例中8例,7.9%)。

关键数值与推荐

  • 癫痫 panel 诊断率29.2%(96例中28例;P<.001)和全外显子27.8%(18例中5例;P=.02)均高于染色体微阵列7.9%(101例中8例)。
  • 结节性硬化症复合体11例中9例(81.8%)、代谢病14例中11例(78.6%)、脑畸形61例中20例(32.8%)的致病性变异检出率较高。

临床怎么用

  • 对新发早期儿童癫痫应初始评估即考虑全面基因检测,尤其强调测序类检测,而非仅限严重表现或不良预后者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Early-life epilepsies are often a consequence of numerous neurodevelopmental disorders, most of which are proving to have genetic origins. The role of genetic testing in the initial evaluation of these epilepsies is not established. OBJECTIVE: To provide a contemporary account of the patterns of use and diagnostic yield of genetic testing for early-life epilepsies. DESIGN, SETTING, AND PARTICIPANTS: In this prospective cohort, children with newly diagnosed epilepsy with an onset at less than 3 years of age were recruited from March 1, 2012, to April 30, 2015, from 17 US pediatric hospitals and followed up for 1 year. Of 795 families approached, 775 agreed to participate. Clinical diagnosis of the etiology of epilepsy were characterized based on information available before genetic testing was performed. Added contributions of cytogenetic and gene sequencing investigations were determined. EXPOSURES: Genetic diagnostic testing. MAIN OUTCOMES AND MEASURES: Laboratory-confirmed pathogenic variant. RESULTS: Of the 775 patients in the study (367 girls and 408 boys; median age of onset, 7.5 months [interquartile range, 4.2-16.5 months]), 95 (12.3%) had acquired brain injuries. Of the remaining 680 patients, 327 (48.1%) underwent various forms of genetic testing, which identified pathogenic variants in 132 of 327 children (40.4%; 95% CI, 37%-44%): 26 of 59 (44.1%) with karyotyping, 32 of 188 (17.0%) with microarrays, 31 of 114 (27.2%) with epilepsy panels, 11 of 33 (33.3%) with whole exomes, 4 of 20 (20.0%) with mitochondrial panels, and 28 of 94 (29.8%) with other tests. Forty-four variants were identified before initial epilepsy presentation. Apart from dysmorphic syndromes, pathogenic yields were highest for children with tuberous sclerosis complex (9 of 11 [81.8%]), metabolic diseases (11 of 14 [78.6%]), and brain malformations (20 of 61 [32.8%]). A total of 180 of 446 children (40.4%), whose etiology would have remained unknown without genetic testing, underwent some testing. Pathogenic variants were identified in 48 of 180 children (26.7%; 95% CI, 18%-34%). Diagnostic yields were greater than 15% regardless of delay, spasms, and young age. Yields were greater for epilepsy panels (28 of 96 [29.2%]; P < .001) and whole exomes (5 of 18 [27.8%]; P = .02) than for chromosomal microarray (8 of 101 [7.9%]). CONCLUSIONS AND RELEVANCE: Genetic investigations, particularly broad sequencing methods, have high diagnostic yields in newly diagnosed early-life epilepsies regardless of key clinical features. Thorough genetic investigation emphasizing sequencing tests should be incorporated into the initial evaluation of newly presenting early-life epilepsies and not just reserved for those with severe presentations and poor outcomes.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Berg AT, Coryell J, Saneto RP, et al. Early-Life Epilepsies and the Emerging Role of Genetic Testing. JAMA Pediatr. 2017. PMID: 28759667. doi:10.1001/jamapediatrics.2017.1743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。